These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jan 5, 2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...
Dec 7, 2020Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /CNW/ - Sierra Oncology,...
Dec 5, 2020Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting
--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a...
Dec 1, 2020Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH
--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan Verstovsek-- VANCOUVER, BC, Dec. 1, 2020 /CNW/ -...
Nov 25, 2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address...